Inflammatory peeling skin syndrome is a rare inherited skin disorder in which the outermost layer of skin sheds continuously from birth, accompanied by persistent redness and intense itching. Caused by mutations in a single gene, the condition belongs to a broader family of peeling skin syndromes but stands apart because of its inflammatory character and its surprising connections to allergies, asthma, and immune dysfunction. Despite being described decades ago, it remains poorly recognized even among dermatologists, and many affected families endure years of misdiagnosis before reaching an answer.
What the Condition Looks Like
The hallmark of inflammatory peeling skin syndrome is superficial, painless shedding of skin that begins at or shortly after birth and never stops. Parents often notice that large sheets or flakes of skin come away with minimal friction, sometimes just from rubbing against clothing or bedsheets. Beneath the peeled areas, the skin is red and inflamed rather than raw or ulcerated. This underlying redness is what earns the condition the label “inflammatory” and separates it from a milder, noninflammatory form of peeling skin syndrome in which the peeling occurs without much visible irritation underneath.
The peeling is generalized, meaning it can affect skin virtually anywhere on the body, though it tends to be most obvious on the trunk and limbs. Thickened, rough patches of skin often appear alongside the peeling areas.
Itching is one of the most distressing features. Affected individuals describe relentless pruritus that worsens in warm weather and can significantly disrupt sleep and daily activities. Recurrent skin infections are common as well, because the barrier that normally keeps bacteria and other pathogens out is constantly compromised.
The Genetic Root
Inflammatory peeling skin syndrome, sometimes called peeling skin syndrome type B or peeling skin disease, follows an autosomal recessive inheritance pattern. That means a child must inherit a faulty copy of the responsible gene from each parent to develop the condition. Carriers who have only one faulty copy typically show no symptoms at all.
The gene at the center of the disorder is CDSN, which provides instructions for making a protein called corneodesmosin. This protein acts as a kind of molecular glue in the uppermost layers of the epidermis, holding skin cells together until they are ready to be shed in the normal, invisible process of desquamation. Corneodesmosin reinforces the tiny rivets, called corneodesmosomes, that lock neighboring cells to one another. In healthy skin, specialized enzymes gradually break down corneodesmosin in a controlled way so that dead skin cells detach individually and imperceptibly.
When both copies of CDSN carry loss-of-function mutations, corneodesmosin is absent or undetectable in the skin. Without that adhesive protein, cells in the outermost layer lose their grip on one another and peel away prematurely, in visible sheets rather than one cell at a time. Researchers identified this mechanism through genome-wide linkage analysis in a large consanguineous family, finding a homozygous nonsense mutation that produced a premature stop signal in the gene and wiped out corneodesmosin expression entirely.
Several distinct mutations in CDSN have now been reported worldwide. Some are single-letter changes in the DNA code that create a premature stop, while others involve small duplications or even complete deletion of the gene. A case reported in Japan, for instance, resulted from a full genomic deletion of the CDSN region, leaving the protein completely undetectable in the epidermis and unamplifiable by standard genetic testing methods. A separate family carried a four-base-pair duplication in the second exon of the gene, producing a frameshift that similarly abolished corneodesmosin. Despite the different mutation types, the downstream effect is the same: the protein is absent, and the skin falls apart.
Why It Triggers Allergies and Immune Problems
If inflammatory peeling skin syndrome were only about peeling, it would be uncomfortable but straightforward. What makes it medically more complex is its strong association with allergic and immune-related conditions. In the large family study that pinpointed CDSN, the affected children showed food allergies to nuts and fish, repeated episodes of hives and angioedema, asthma, and dramatically elevated levels of immunoglobulin E, the antibody class that drives allergic reactions.
The link is not coincidental. When the skin barrier is chronically broken, environmental allergens, microbes, and irritants gain easy access to the deeper layers of skin where immune cells reside. The immune system responds by ramping up inflammation. Research using three-dimensional human skin models built from patient cells showed that the absence of corneodesmosin creates a measurable barrier defect, with molecules passing through the skin far more readily than through normal skin. This leaky barrier is thought to prime the body for the kind of exaggerated immune responses seen in atopic diseases.
Researchers have drawn explicit parallels between inflammatory peeling skin syndrome and better-known barrier disorders like Netherton syndrome and the common form of eczema linked to filaggrin gene variants. All three conditions share the basic pattern of a broken skin barrier followed by immune overactivation, elevated IgE, and a predisposition to allergies. Inflammatory peeling skin syndrome has been proposed as a model disorder for studying atopic disease more broadly, because the barrier defect is so severe and the genetic cause so clearly defined.
What Happens at the Immune Level
Animal studies have offered a closer look at the immune cascades triggered when corneodesmosin is missing. Researchers created mice in which the CDSN gene could be selectively switched off in skin cells. When the epidermal barrier broke down in these animals, two major inflammatory pathways fired up simultaneously. One was driven by a signaling molecule called thymic stromal lymphopoietin (TSLP), which promotes a type 2 immune response, the same arm of immunity responsible for allergic reactions. The other was driven by interleukin-23, which promotes a type 17 response more commonly associated with psoriasis-like inflammation.
These two pathways did not simply pile on top of each other. Instead, they appeared to counterregulate one another, each partially restraining the other. That push-and-pull between competing immune programs helps explain why the skin inflammation in this syndrome does not look exactly like classic eczema or classic psoriasis but has features of both. The mouse work also suggested that blocking interleukin-1 signaling, a step upstream of both pathways, could be a promising way to tamp down the inflammation, an idea that has not yet been tested in human patients with the condition.
Elevated activity of kallikrein 5, one of the enzymes that normally degrades corneodesmosin in a controlled fashion, has also been documented in patient skin models. When corneodesmosin is absent, the regulatory balance of these proteases goes awry. Their unchecked activity may further damage surrounding tissue and amplify the inflammatory signals already being generated by the barrier breach.
Getting the Diagnosis Right
Because the condition is so rare, many affected individuals are initially misdiagnosed with more common skin disorders. Eczema, psoriasis, and various forms of ichthyosis can all produce red, flaky skin, and unless a clinician thinks specifically about peeling skin syndrome, it is easy to default to one of those labels. The generalized nature of the peeling, its onset at birth, and its resistance to standard eczema treatments are clues that something more unusual is going on.
Skin biopsy is an important early step. Under the microscope, the characteristic finding is a split either within the stratum corneum or just below it, above the granular layer. This superficial cleavage pattern is different from the deeper splits seen in blistering disorders and helps narrow the diagnosis.
The condition most commonly confused with inflammatory peeling skin syndrome is Netherton syndrome, another inherited barrier disorder that shares features like redness, scaling, elevated IgE, and allergic tendencies. Netherton syndrome is caused by mutations in a different gene, SPINK5, and produces a deficiency of a protein called LEKTI. Immunohistochemical staining of skin for LEKTI can help distinguish the two: normal LEKTI staining argues against Netherton syndrome and points toward a CDSN-related diagnosis instead. One reported case involved a child with generalized inflammatory peeling, marked eosinophilia, and an unusual hair shaft abnormality called trichorrhexis invaginata, features that initially suggested Netherton syndrome. Normal LEKTI staining and subsequent genetic testing revealed a novel complete CDSN deletion, confirming inflammatory peeling skin syndrome.
Genetic testing has become the definitive diagnostic tool. Sequencing the CDSN gene can identify the specific mutation, confirm the diagnosis, and inform genetic counseling for the family. As more mutations are catalogued, the turnaround time and accessibility of this testing continue to improve, though it remains specialist-level work in most countries.
Systemic Complications Worth Watching For
Beyond the skin and the allergic tendencies, inflammatory peeling skin syndrome can occasionally affect other organ systems. At least one case has documented immunoglobulin A nephropathy, a kidney condition, developing in association with the syndrome. The patient had experienced generalized skin peeling since birth along with recurrent purulent skin infections, and the kidney involvement added a new layer of medical complexity.
Whether kidney disease is a direct consequence of chronic immune activation, a coincidence, or a rare complication seen only in certain genetic backgrounds is unclear given the small number of known cases. The broader point is that a chronic barrier defect flooding the immune system with antigens and driving persistent inflammation can have downstream effects beyond the skin itself. Clinicians managing affected patients generally monitor for signs of systemic immune dysregulation, including periodic blood work to track IgE levels, eosinophil counts, and kidney function.
Recurrent skin infections deserve special mention as a practical concern. The compromised barrier invites bacterial colonization, and infections can range from superficial impetigo-like lesions to deeper, more troublesome episodes. Proactive skin hygiene, prompt treatment of infections, and awareness of warning signs are a routine part of managing the condition day to day.
Treatment Options and Their Limits
There is currently no cure for inflammatory peeling skin syndrome, and treatment remains largely supportive. The mainstays are emollients to reduce moisture loss and protect the fragile skin surface, topical anti-inflammatory agents to manage flare-ups of redness and itching, and antihistamines to blunt the itching driven by elevated IgE. Avoiding excessive heat, which worsens itching, and maintaining a consistent moisturizing routine are practical strategies that can meaningfully improve comfort.
Given the condition’s overlap with atopic disease, there has been interest in whether biologic drugs designed for eczema and allergies could help. Dupilumab, which blocks interleukin-4 and interleukin-13 signaling and is widely used for moderate-to-severe atopic dermatitis, was tried in at least one patient with peeling skin syndrome type 1. While the drug successfully lowered IgE levels, it did not improve the skin peeling or other cutaneous abnormalities. That outcome makes sense in hindsight: the fundamental problem is a structural one, a missing adhesive protein, and dampening downstream immune signals does not restore the glue that holds the skin together. The allergic symptoms may improve with immune-targeted therapy, but the peeling itself persists because its cause is mechanical, not purely inflammatory.
The mouse studies pointing to interleukin-1 signaling as a potential therapeutic target have not yet led to human trials, but they represent one of the few leads for a more targeted approach. If blocking IL-1 could reduce the inflammatory component without needing to fix the underlying adhesion defect, it might at least lessen the redness, itching, and immune overactivation that make the condition so burdensome. For now, though, this remains experimental.
Management of food allergies, asthma, and angioedema follows the same principles used for those conditions in general, with the added awareness that these patients may be especially prone to severe allergic reactions because of their chronic barrier breach. Carrying epinephrine auto-injectors and having a clear allergy action plan are standard recommendations for affected individuals with documented food allergies.
Inheritance and What It Means for Families
Because the syndrome is autosomal recessive, both parents of an affected child are obligate carriers. Each subsequent pregnancy carries a one-in-four chance of producing another affected child, a one-in-two chance of producing a carrier, and a one-in-four chance of producing a child with two normal copies of the gene. Carrier parents are clinically unaffected.
The condition is disproportionately reported in families with consanguinity, meaning the parents share a degree of biological relatedness. This is expected for any rare recessive trait: when the carrier frequency in the general population is very low, the odds of two unrelated carriers meeting and having children are slim, while the odds increase substantially when parents share ancestry. The large family in which the CDSN mutation was first identified through linkage analysis was consanguineous, as were several other reported families. However, the condition can and does occur in non-consanguineous families when both parents happen to carry mutations in the same gene.
Genetic counseling is valuable for affected families, particularly if further pregnancies are planned. Once the specific mutation is known, prenatal or preimplantation genetic testing becomes straightforward. Carrier testing for extended family members is also possible and sometimes requested, especially in communities where the carrier frequency may be higher due to founder effects.
Hair and Nail Involvement
Corneodesmosin is not found exclusively in the interfollicular epidermis. It is also expressed in the inner root sheath of hair follicles, the structure that guides the growing hair shaft as it moves toward the skin surface. Mouse models in which the CDSN gene was knocked out showed that while hair follicles appeared normal at birth, they degenerated over time, revealing that corneodesmosin is required for hair-follicle integrity as well.
In human patients, hair abnormalities are variable. Some individuals have relatively normal hair, while others experience thinning, fragility, or unusual shaft defects. One case report described trichorrhexis invaginata, a distinctive “bamboo hair” defect more classically associated with Netherton syndrome, appearing in a child ultimately diagnosed with CDSN deletion. This overlap in hair findings further illustrates why clinical distinction between the two syndromes can be tricky without genetic confirmation.
Interestingly, specific dominant mutations in the same CDSN gene can cause a completely different condition, hereditary hypotrichosis simplex, which involves hair loss without the peeling skin phenotype. The contrast underscores that the type and location of a mutation within a gene can produce dramatically different clinical pictures. Complete loss of corneodesmosin leads to peeling skin disease, while certain missense mutations that alter the protein without eliminating it may selectively affect hair follicles.
Why It Matters Beyond Rare Disease
Fewer than a hundred cases of inflammatory peeling skin syndrome have been described in the medical literature, making it one of the rarest inherited skin conditions known. Yet its significance extends well beyond the small number of affected families. The condition provides a uniquely clean genetic model for understanding how skin barrier failure leads to atopic disease. In common eczema, multiple genes, environmental factors, and immune variables interact in ways that are difficult to untangle. In inflammatory peeling skin syndrome, a single gene deletion produces a complete barrier collapse followed by the full spectrum of atopic consequences: elevated IgE, food allergy, asthma, urticaria, and angioedema. Studying these patients and the corresponding animal models has helped researchers understand the step-by-step immune cascade that unfolds when the skin barrier breaks down, knowledge that feeds back into treatment development for far more common conditions like atopic dermatitis.
The mouse models, in particular, have been revealing. The finding that TSLP-driven and IL-23-driven inflammation arise simultaneously and regulate each other in barrier-defective skin was first demonstrated in corneodesmosin-knockout mice and has since informed thinking about immune pathways in eczema and psoriasis overlap states. For families living with the condition, these research advances offer the hope that targeted therapies will eventually emerge. For the broader dermatology and immunology fields, the syndrome serves as a living experiment in what happens when one critical piece of the skin’s architecture is removed entirely.